% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Ramaswamy:130384,
author = {V. Ramaswamy and T. Hielscher$^*$ and S. C. Mack and A.
Lassaletta and T. Lin and K. Pajtler$^*$ and D. Jones$^*$
and B. Luu and F. M. G. Cavalli and K. Aldape and M. Remke
and M. Mynarek and S. Rutkowski and S. Gururangan and R. E.
McLendon and E. S. Lipp and C. Dunham and J. Hukin and D. D.
Eisenstat and D. Fulton and F. K. H. van Landeghem and M.
Santi and M. C. van Veelen and E. G. Van Meir and S. Osuka
and X. Fan and K. M. Muraszko and D. P. C. Tirapelli and S.
M. Oba-Shinjo and S. K. N. Marie and C. G. Carlotti and J.
Y. Lee and A. A. N. Rao and C. Giannini and C. C. Faria and
S. Nunes and J. Mora and R. L. Hamilton and P. Hauser and N.
Jabado and K. Petrecca and S. Jung and L. Massimi and M.
Zollo and G. Cinalli and L. Bognár and A. Klekner and T.
Hortobágyi and S. Leary and R. P. Ermoian and J. M. Olson
and J. R. Leonard and C. Gardner and W. A. Grajkowska and L.
B. Chambless and J. Cain and C. G. Eberhart and S. Ahsan and
M. Massimino and F. Giangaspero and F. R. Buttarelli and R.
J. Packer and L. Emery and W. H. Yong and H. Soto and L. M.
Liau and R. Everson and A. Grossbach and T. Shalaby and M.
Grotzer and M. A. Karajannis and D. Zagzag and H. Wheeler
and K. von Hoff and M. M. Alonso and T. Tuñon and U.
Schüller and K. Zitterbart and J. Sterba and J. A. Chan and
M. Guzman and S. K. Elbabaa and H. Colman and G. Dhall and
P. G. Fisher and M. Fouladi and A. Gajjar and S. Goldman and
E. Hwang and M. Kool$^*$ and H. Ladha and E. Vera-Bolanos
and K. Wani and F. Lieberman and T. Mikkelsen and A. M.
Omuro and I. F. Pollack and M. Prados and H. I. Robins and
R. Soffietti and J. Wu and P. Metellus and U. Tabori and U.
Bartels and E. Bouffet and C. E. Hawkins and J. T. Rutka and
P. Dirks and S. Pfister$^*$ and T. E. Merchant and M. R.
Gilbert and T. S. Armstrong and A. Korshunov$^*$ and D. W.
Ellison and M. D. Taylor},
title = {{T}herapeutic {I}mpact of {C}ytoreductive {S}urgery and
{I}rradiation of {P}osterior {F}ossa {E}pendymoma in the
{M}olecular {E}ra: {A} {R}etrospective {M}ulticohort
{A}nalysis.},
journal = {Journal of clinical oncology},
volume = {34},
number = {21},
issn = {1527-7755},
address = {Alexandria, Va.},
publisher = {American Society of Clinical Oncology},
reportid = {DKFZ-2017-05463},
pages = {2468 - 2477},
year = {2016},
abstract = {Posterior fossa ependymoma comprises two distinct molecular
variants termed $EPN_PFA$ and $EPN_PFB$ that have a distinct
biology and natural history. The therapeutic value of
cytoreductive surgery and radiation therapy for posterior
fossa ependymoma after accounting for molecular subgroup is
not known.Four independent nonoverlapping retrospective
cohorts of posterior fossa ependymomas (n = 820) were
profiled using genome-wide methylation arrays. Risk
stratification models were designed based on known clinical
and newly described molecular biomarkers identified by
multivariable Cox proportional hazards analyses.Molecular
subgroup is a powerful independent predictor of outcome even
when accounting for age or treatment regimen. Incompletely
resected $EPN_PFA$ ependymomas have a dismal prognosis, with
a 5-year progression-free survival ranging from $26.1\%$ to
$56.8\%$ across all four cohorts. Although first-line
(adjuvant) radiation is clearly beneficial for completely
resected $EPN_PFA,$ a substantial proportion of patients
with $EPN_PFB$ can be cured with surgery alone, and patients
with relapsed $EPN_PFB$ can often be treated successfully
with delayed external-beam irradiation.The most impactful
biomarker for posterior fossa ependymoma is molecular
subgroup affiliation, independent of other demographic or
treatment variables. However, both $EPN_PFA$ and $EPN_PFB$
still benefit from increased extent of resection, with the
survival rates being particularly poor for subtotally
resected $EPN_PFA,$ even with adjuvant radiation therapy.
Patients with $EPN_PFB$ who undergo gross total resection
are at lower risk for relapse and should be considered for
inclusion in a randomized clinical trial of observation
alone with radiation reserved for those who experience
recurrence.},
cin = {C060 / G380 / B062},
ddc = {050},
cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)G380-20160331 /
I:(DE-He78)B062-20160331},
pnm = {319H - Addenda (POF3-319H)},
pid = {G:(DE-HGF)POF3-319H},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:27269943},
pmc = {pmc:PMC4962737},
doi = {10.1200/JCO.2015.65.7825},
url = {https://inrepo02.dkfz.de/record/130384},
}